Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
N/ANon-phased studies
5(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
N/A

Trials by Phase

N/A5 (100.0%)

Trials by Status

terminated120%
unknown120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

MRgFUS in the Treatment of Hand and Hip Osteoarthritic Pain

NCT03467165
completednot_applicable

MRgFUS in the Treatment of Osteoarthritic Knee Pain

NCT03453372
terminatednot_applicable

A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor

NCT03253991
unknownnot_applicable

MRgFUS Thalamotomy for Therapy-Resistant Tremor-related Disease With Low SDR Value

NCT05624385
completednot_applicable

Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study

NCT01226576

Clinical Trials (5)

Showing 5 of 5 trials
NCT03467165Not Applicable

MRgFUS in the Treatment of Hand and Hip Osteoarthritic Pain

Completed
NCT03453372Not Applicable

MRgFUS in the Treatment of Osteoarthritic Knee Pain

Completed
NCT03253991Not Applicable

A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor

Terminated
NCT05624385Not Applicable

MRgFUS Thalamotomy for Therapy-Resistant Tremor-related Disease With Low SDR Value

Unknown
NCT01226576Not Applicable

Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study

Completed

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5